萬隆控股集團(00030.HK)訂立營養保健品開發合作框架協議
萬隆控股集團(00030.HK)公布,與於泰國註冊成立與DOD Biotech訂立戰略合作框架協議,內容有關就營養保健品之開發及商業化進行合作,為期三年。
DOD Biotech將為製造營養保健品而貢獻其產品配方經驗和質量保證能力;集團將貢獻其在亞洲之銷售網絡,以及在功能性草藥成分及傳統中藥方面之知識,以評估營養保健品之市場潛力;訂約方應注入本身之資源、專業訣竅及經驗以支持營養保健品的研發。對於根據框架協議開發的任何營養保健品,訂約方應合作將有關產品註冊在公司名下。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.